HUS1500043I1 - Eljárások Parkinson-kór kezelésére - Google Patents

Eljárások Parkinson-kór kezelésére

Info

Publication number
HUS1500043I1
HUS1500043I1 HUS1500043C HUS1500043C HUS1500043I1 HU S1500043 I1 HUS1500043 I1 HU S1500043I1 HU S1500043 C HUS1500043 C HU S1500043C HU S1500043 C HUS1500043 C HU S1500043C HU S1500043 I1 HUS1500043 I1 HU S1500043I1
Authority
HU
Hungary
Prior art keywords
parkinson
disease
treatment
methods
Prior art date
Application number
HUS1500043C
Other languages
English (en)
Hungarian (hu)
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1500043(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of HUS1500043I1 publication Critical patent/HUS1500043I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUS1500043C 2003-04-11 2015-07-22 Eljárások Parkinson-kór kezelésére HUS1500043I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
EP04726590A EP1613296B1 (en) 2003-04-11 2004-04-08 Methods for treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
HUS1500043I1 true HUS1500043I1 (hu) 2018-11-28

Family

ID=33159845

Family Applications (1)

Application Number Title Priority Date Filing Date
HUS1500043C HUS1500043I1 (hu) 2003-04-11 2015-07-22 Eljárások Parkinson-kór kezelésére

Country Status (28)

Country Link
US (3) US8283380B2 (https=)
EP (2) EP2070526B1 (https=)
JP (2) JP2006522800A (https=)
KR (2) KR20110070929A (https=)
CN (2) CN102274517B (https=)
AR (1) AR044007A1 (https=)
AT (1) ATE435012T1 (https=)
AU (1) AU2004228782B2 (https=)
BR (1) BRPI0409364A (https=)
CA (1) CA2523188C (https=)
CY (3) CY1109295T1 (https=)
DE (1) DE602004021790D1 (https=)
DK (2) DK1613296T3 (https=)
ES (2) ES2454272T3 (https=)
FR (1) FR15C0054I2 (https=)
HU (1) HUS1500043I1 (https=)
IL (2) IL171331A (https=)
LU (1) LU92782I2 (https=)
MX (1) MXPA05010873A (https=)
NL (1) NL300752I2 (https=)
NO (3) NO334316B1 (https=)
NZ (1) NZ542910A (https=)
PL (2) PL1613296T3 (https=)
PT (2) PT1613296E (https=)
RU (1) RU2342929C2 (https=)
SI (2) SI1613296T1 (https=)
TW (1) TWI340640B (https=)
WO (1) WO2004089353A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
DK1423168T3 (da) * 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
DK1658062T3 (da) * 2003-08-25 2010-05-31 Newron Pharm Spa Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
US20100092554A1 (en) * 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
CA2689561C (en) 2007-06-15 2015-11-17 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
US8530701B2 (en) 2007-12-11 2013-09-10 Newron Pharmaceuticals, S.P.A. High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
NZ586182A (en) * 2007-12-19 2012-02-24 Newron Pharm Spa Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
WO2009147432A1 (en) * 2008-06-02 2009-12-10 Generics [Uk] Limited An improved process for the preparation of amines
CN103896779B (zh) * 2008-06-02 2015-12-30 基因里克斯(英国)有限公司 用于制备对映异构纯胺的方法
US8969417B2 (en) * 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
SI2563355T1 (sl) 2010-04-27 2016-10-28 Newron Pharmaceuticals S.P.A. Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
ES2608782T3 (es) 2010-04-30 2017-04-17 Teikoku Pharma Usa, Inc. Composiciones transdérmicas de propinilaminoindano
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US10196341B2 (en) 2011-08-19 2019-02-05 The Trustees Of Princeton University C-halogen bond formation
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
KR20210075224A (ko) 2012-10-22 2021-06-22 키비타스 테라퓨틱스, 인코포레이티드. 파킨슨병의 빠른 경감을 위한 레보도파 제형
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
WO2014210544A2 (en) * 2013-06-27 2014-12-31 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
EP3134077A4 (en) * 2014-04-21 2017-12-20 Civitas Therapeutics, Inc. Rapid relief of motor fluctuations in parkinson's disease
CN106795098B (zh) * 2014-10-02 2020-07-14 默加拜奥伍德有限公司 α-氨基酰胺衍生化合物及包含其的药物组合物
PT3341380T (pt) * 2015-08-27 2019-12-19 Prexton Therapeutics Sa Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa
WO2017161155A1 (en) * 2016-03-17 2017-09-21 The Johns Hopkins University Methods for preventing or treating parkinson's disease by the farnesylation of paris
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (en) * 2017-01-14 2018-07-19 Mischley Laurie Kathern Method of using human excrement and secretions for early detection of parkinson's disease
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
US11234961B2 (en) * 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
WO2019086408A1 (en) 2017-11-02 2019-05-09 Zambon S.P.A. Pharmaceutical compositions comprising safinamide
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
LU101477B1 (en) * 2019-11-12 2021-05-14 Univ Luxembourg An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
WO2022047298A1 (en) * 2020-08-31 2022-03-03 Purdue Pharma L.P. Compositions and methods for levodopa delivery
KR20230154249A (ko) * 2021-03-08 2023-11-07 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료
KR102790040B1 (ko) * 2021-06-24 2025-04-01 연세대학교 산학협력단 도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ATE258067T1 (de) * 1995-05-26 2004-02-15 Pfizer Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
AU2004228782B2 (en) 2010-05-20
NL300752I2 (https=) 2016-07-05
PT1613296E (pt) 2009-07-30
NO335537B1 (no) 2014-12-22
CA2523188A1 (en) 2004-10-21
NO2015018I2 (no) 2015-07-23
ES2454272T3 (es) 2014-04-10
NO334316B1 (no) 2014-02-03
FR15C0054I1 (fr) 2015-11-09
ATE435012T1 (de) 2009-07-15
ES2326373T3 (es) 2009-10-08
KR101129015B1 (ko) 2012-04-20
PL1613296T3 (pl) 2009-12-31
SI2070526T1 (sl) 2014-05-30
NZ542910A (en) 2007-10-26
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
IL216403A (en) 2015-01-29
EP2070526B1 (en) 2014-02-26
TWI340640B (en) 2011-04-21
US20130053368A1 (en) 2013-02-28
FR15C0054I2 (fr) 2018-01-26
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
NO2015018I1 (no) 2015-08-03
JP2013067647A (ja) 2013-04-18
AR044007A1 (es) 2005-08-24
EP1613296A2 (en) 2006-01-11
CY2015025I2 (el) 2016-04-13
RU2342929C2 (ru) 2009-01-10
LU92782I2 (fr) 2015-09-22
CA2523188C (en) 2012-09-25
SI1613296T1 (sl) 2009-10-31
TW200505423A (en) 2005-02-16
RU2005131422A (ru) 2006-04-27
DK2070526T3 (da) 2014-03-24
EP1613296B1 (en) 2009-07-01
NO20131417L (no) 2005-12-09
WO2004089353A8 (en) 2005-09-01
KR20110070929A (ko) 2011-06-24
CN102274517A (zh) 2011-12-14
KR20060010745A (ko) 2006-02-02
CY2015025I1 (el) 2016-04-13
JP2006522800A (ja) 2006-10-05
NO20054640D0 (no) 2005-10-10
BRPI0409364A (pt) 2006-04-25
DK1613296T3 (da) 2009-10-05
WO2004089353A3 (en) 2004-12-16
US8283380B2 (en) 2012-10-09
IL171331A (en) 2012-03-29
PT2070526E (pt) 2014-03-31
EP2070526A1 (en) 2009-06-17
PL2070526T3 (pl) 2014-08-29
MXPA05010873A (es) 2006-03-21
WO2004089353A2 (en) 2004-10-21
US8901176B2 (en) 2014-12-02
US20150150833A1 (en) 2015-06-04
CY1109295T1 (el) 2014-07-02
IL216403A0 (en) 2011-12-29
US9492410B2 (en) 2016-11-15
AU2004228782A1 (en) 2004-10-21
CN102274517B (zh) 2018-08-31
CN1771030A (zh) 2006-05-10

Similar Documents

Publication Publication Date Title
HUS1500043I1 (hu) Eljárások Parkinson-kór kezelésére
AU2003286567A8 (en) Methods for the treatment of skin disorders
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
GB0329874D0 (en) Compounds useful for the treatment of diseases
GB0320238D0 (en) Treatment of disease
IL173351A0 (en) Therapy of ocular disorders
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003228464A1 (en) Apparatus for treatment of meniere's disease
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
IL180513A0 (en) Process for synthesis of 4-4'-diamino-diphenyl-sulfone
AU2003284898A1 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
EP1693671A4 (en) METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
EP1513550A4 (en) NEW BACTERIUM FOR THE TREATMENT OF DISEASES
AU2003277298A8 (en) Pharmaceutical compositions for treatment of parkinson's disease
GB0410101D0 (en) Parkinson's disease
AU2003297912A8 (en) Methods for screening compounds for use in the treatment of disease
GB0327975D0 (en) Methods of treatment
AU2003216696A8 (en) Methods for the selection of compounds useful for the treatment of huntington's disease
EP1863510A4 (en) METHOD FOR TREATING PARKINSON DISEASE
AU2004907196A0 (en) Use of Naltrexone for Treating Alzheimer's Disease
AU2003300471A8 (en) Methods for treating ocular diseases